Accession Number : ADA462669


Title :   Effects of Androgen Ablation on Anti-Tumor Immunity


Descriptive Note : Final rept. 1 Sep 2002-31 Aug 2006


Corporate Author : UNIVERSITY OF SOUTHERN CALIFORNIA LOS ANGELES


Personal Author(s) : Kast, W. M.


Full Text : http://www.dtic.mil/get-tr-doc/pdf?AD=ADA462669


Report Date : SEP 2006


Pagination or Media Count : 46


Abstract : Androgen Ablation (AA) constitutes the most common therapy for the treatment of advanced prostate cancer. While initially effective at reducing tumor burden, most patients recur with androgen insensitive disease. AA affects the immune system both systemically as well as at the prostate. Androgens have immunosuppressive effects and it is therefore of interest to investigate if immunotherapy can benefit from androgen ablation when immunosuppression is reduced. AA results in infiltration of activated T cells, dendritic cells (DCs) and macrophages into the prostate. DCs are the only antigen-presenting cells that can activate naive T cells to a novel antigen and are the key players of successful vaccination regimes. Many DC-directed prostate cancer immunotherapy strategies are in clinical trials but there is little information with regards to the effects of androgen ablation on DC function. We have set forth to investigate the effects of androgen ablation on DC costimulation. The ultimate goal of studying the effects of AA on the immune system is to determine if a prostate-directed immunotherapy strategy can benefit from androgen ablation and we have directly tested this in an antigen-specific manner using a prostate-specific antigen, six transmembrane epithelial antigen of the prostate (STEAP).


Descriptors :   *SUPPRESSION , *ANDROGENS , *IMMUNOTHERAPY , *PROSTATE CANCER , ABLATION , STIMULATION(PHYSIOLOGY) , CLINICAL TRIALS , ANTIGENS


Subject Categories : BIOCHEMISRTY
      MEDICINE AND MEDICAL RESEARCH


Distribution Statement : APPROVED FOR PUBLIC RELEASE